Published: June 19th 2024 | Updated: June 24th 2024
Utilizing Biomarkers to Develop First-in-Class Antibody Drug Conjugates to Treat Advanced Solid Tumors
Published: November 5th 2024 | Updated: December 6th 2024
FDA Challenges to Broad Label Laws for PD-1 Inhibitors
Published: November 18th 2024 | Updated: December 6th 2024
Rationale Behind the Recent FDA PD-1 Inhibitor Label Restrictions
Published: November 20th 2024 | Updated: December 6th 2024
The Influence of PD-1 Inhibitor Label Restrictions on Future Studies
Published: November 19th 2024 | Updated: December 6th 2024
Potential Legal Action Against PD-1 Inhibitor Label Restrictions for Gastric Cancers
Published: November 25th 2024 | Updated: December 6th 2024
FDA Expands Labeling for Roche’s Pathway Rabbit Monoclonal Primary Antibody in Patients with Biliary Tract Cancer